Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (Review)

  • Authors:
    • Zuzana Solárová
    • Ján Mojžiš
    • Peter Solár
  • View Affiliations

  • Published online on: December 10, 2014     https://doi.org/10.3892/ijo.2014.2791
  • Pages: 907-926
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Hsp90 is a molecular chaperone that maintains the structural and functional integrity of various client proteins involved in signaling and many other functions of cancer cells. The natural inhibitors, ansamycins influence the Hsp90 chaperone function by preventing its binding to client proteins and resulting in their proteasomal degradation. N- and C-terminal inhibitors of Hsp90 and their analogues are widely tested as potential anticancer agents in vitro, in vivo as well as in clinical trials. It seems that Hsp90 competitive inhibitors target different tumor types at nanomolar concentrations and might have therapeutic benefit. On the contrary, some Hsp90 inhibitors increased toxicity and resistance of cancer cells induced by heat shock response, and through the interaction of survival signals, that occured as side effects of treatments, could be very effectively limited via combination of therapies. The aim of our review was to collect the data from experimental and clinical trials where Hsp90 inhibitor was combined with other therapies in order to prevent resistance as well as to potentiate the cytotoxic and/or antiproliferative effects.
View References

Related Articles

Journal Cover

March-2015
Volume 46 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Solárová Z, Mojžiš J and Solár P: Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (Review). Int J Oncol 46: 907-926, 2015
APA
Solárová, Z., Mojžiš, J., & Solár, P. (2015). Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (Review). International Journal of Oncology, 46, 907-926. https://doi.org/10.3892/ijo.2014.2791
MLA
Solárová, Z., Mojžiš, J., Solár, P."Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (Review)". International Journal of Oncology 46.3 (2015): 907-926.
Chicago
Solárová, Z., Mojžiš, J., Solár, P."Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (Review)". International Journal of Oncology 46, no. 3 (2015): 907-926. https://doi.org/10.3892/ijo.2014.2791